Jan Pander

Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative)

Joanne R Chalmers, Eric L. Simpson, Christian Apfelbacher et al. · British Journal of Dermatology · 2016 · 124 citations · Full text

Medicine, Dermatology, Allergy +15

Activation of Tumor-Promoting Type 2 Macrophages by EGFR-Targeting Antibody Cetuximab

Jan Pander, Moniek Heusinkveld, Tahar van der Straaten et al. · Clinical Cancer Research · 2011 · 102 citations · Full text

Life Sciences, Immunology, Oncology +17

Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer

Jan Pander, Hans Gelderblom, Ninja Antonini et al. · European Journal of Cancer · 2010 · 82 citations

Medicine, Genetics, Oncology +10

Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer

Jan Pander, Judith A.M. Wessels, Hans Gelderblom et al. · Annals of Oncology · 2010 · 42 citations · Full text

Medicine, Oncology, Pharmacology +16

Treatment duration of febrile urinary tract infection (FUTIRST trial): a randomized placebo-controlled multicenter trial comparing short (7 days) antibiotic treatment with conventional treatment (14 days)

Cees van Nieuwkoop, J. W. van’t Wout, Willem JJ Assendelft et al. · BMC Infectious Diseases · 2009 · 21 citations · Full text

Pharmacy, Pharmacotherapy, Antimicrobial Pharmacology +13